These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16850327)

  • 61. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 62. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.
    Kagami T; Sugimoto M; Ichikawa H; Sahara S; Uotani T; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1467-75. PubMed ID: 26427705
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
    Spechler SJ; Barker PN; Silberg DG
    Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.
    Banerjee R; Reddy DN; Guda NM; Kalpala R; Mahurkar S; Darisetty S; Rao GV
    J Gastroenterol Hepatol; 2010 Jan; 25(1):43-7. PubMed ID: 19874444
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers.
    Niazi M; Andersson T; Nauclér E; Sundin M; Naesdal J
    Int J Clin Pharmacol Ther; 2009 Sep; 47(9):564-9. PubMed ID: 19761715
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies.
    Wilder-Smith CH; Bondarov P; Lundgren M; Niazi M; Röhss K; Ahlbom H; Nyman L
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):191-7. PubMed ID: 15674097
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
    Spechler SJ; Sharma P; Traxler B; Levine D; Falk GW
    Am J Gastroenterol; 2006 Sep; 101(9):1964-71. PubMed ID: 16848802
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
    Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
    Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
    Nishino M; Sugimoto M; Kodaira C; Yamade M; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
    Dig Dis Sci; 2010 Jun; 55(6):1627-36. PubMed ID: 19672708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
    Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
    Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of dose and diet on the pharmacodynamics of esomeprazole in the horse.
    Sykes BW; Underwood C; Mills PC
    Equine Vet J; 2017 Sep; 49(5):637-642. PubMed ID: 28117490
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
    Vo L; Simonian HP; Doma S; Fisher RS; Parkman HP
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1321-30. PubMed ID: 15932362
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H; Nie YQ; Dai SJ; She QZ; Li YY
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
    Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
    Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
    Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
    Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
    Adachi K; Komazawa Y; Fujishiro H; Mihara T; Ono M; Yuki M; Kawamura A; Karim Rumi MA; Amano Y; Kinoshita Y
    J Gastroenterol; 2003; 38(9):830-5. PubMed ID: 14564627
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison.
    Furuta K; Kohata Y; Fujiwara Y; Sugimoto M; Uotani T; Yamade M; Sahara S; Ichikawa H; Furuta T; Nio K; Iwakiri R; Inamori M; Kawamura O; Kusano M; Kato M; Kawami N; Iwakiri K; Takeuchi T; Higuchi K; Aimi M; Naora K; Fujimoto K; Arakawa T; Kinoshita Y
    J Clin Biochem Nutr; 2014 Nov; 55(3):178-83. PubMed ID: 25411523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.
    Tutuian R; Katz PO; Bochenek W; Castell DO
    Aliment Pharmacol Ther; 2002 Apr; 16(4):829-36. PubMed ID: 11929403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.